Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beersel – page 57

1 950 clinical trials in Beersel, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beersel at a glance
1 950
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 950 trials in Beersel

Open in trial search

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Antwerp University Hospital

Study on Minocycline and Celecoxib for Patients with Major Depressive Disorder Not Responding to Antidepressants

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Celecoxib
  • Sponsor:University Of Antwerp

Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Universitair Medisch Centrum Groningen

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Cystic fibrosis

Recruiting

Study on Long-Term Safety and Effectiveness of Vanzacaftor, Tezacaftor, and Deutivacaftor for Cystic Fibrosis in Patients Aged 1 Year and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of Microdystrophin (GNT0004) Gene Therapy for Duchenne Muscular Dystrophy in Boys Who Can Walk

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Genethon

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm

Recruiting

Study on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alizapride
  • Sponsor:Institut Jules Bordet

Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Takeda Development Center Americas Inc.

Study on Atypical Teratoid/Rhabdoid Tumors in Children Using Dactinomycin, Carboplatin, and Cyclophosphamide

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beersel

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, exploring innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Episode Reduction
  • Long-term Control

Research evaluating a novel treatment's effectiveness in reducing the frequency of herpes episodes over a 12-month period, with particular attention to patients experiencing six or more outbreaks annually.

02 Therapeutic Development

Conducting controlled studies to assess the efficacy of 2LHERP®, a potential breakthrough treatment for managing recurring viral infections.

  • Treatment Efficacy
  • Symptom Control
  • Patient Response

The research employs rigorous methodology including placebo control and double-blind protocols to ensure reliable evaluation of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.